Early Phase Clinical Trials 2015

Submit A Letter of Intent

Sign in to our online system or register for a new account to submit a letter of intent.

Apply Now

Neurodegenerative Diseases of Aging

The Early Phase Clinical Trials program is a unique and innovative funding opportunity designed to help outstanding Canadian researchers accelerate the development of safer and more effective treatments for neurodegenerative diseases of aging. Projects should have demonstrated excellent preliminary data and be focused on generating results to support the next stage of clinical trials.

Funding

The program provides up to $1,500,000 for up to 4 years for Phase I and II clinical trials. In previous years, at least 80% of proposals have been funded.

Eligibility Criteria

The Principal applicant must be a researcher(s) with a full-time staff or faculty appointment (at or above the level of Assistant Professor or equivalent) at institutions that are registered CRA qualified donees in Canada.

Projects must focus on the development of therapeutics for the symptomatic relief, disease modification, or prevention of neurodegenerative diseases of aging as we define them (AD, PD, ALS, DLB, FTD, PSP, MSA, and MCI as prodromal to one of these disease). All approaches below qualify for this funding opportunity:

  • Pharmacological approaches (small molecules, biologics, cell therapies, vaccines, including drug repositioning and repurposing)
  • Medical Devices
  • Surgical Interventions
  • Magnetic or electrical brain stimulation

** Complementary approaches (e.g. exercise, acupuncture, foods, or dietary or nutritional supplements) are not included.

Application Process

Program Information Session:        Tuesday, August 4, 2015 1:00 -2:00 p.m. EDT
Letter of Intent (LOI) Deadline:       Tuesday, September 1, 2015, 2:00 p.m. EDT
Proposal Deadline:                                Tuesday, January 12, 2016, 2:00 p.m. EDT
Anticipated Award Notification:     February 2016

*Dates may change

There are two stages to the application process:

    1. Letters of Intent
    2. Proposals

Our application process is both prescriptive and descriptive. First, applicants submit a short letter of intent (LOI). Applicants with high potential projects will be invited to submit a Proposal; instructions will be forwarded along with the invitation.

At each stage, we provide clear, unambiguous guidelines for submissions, which outline the information needed to make a good decision about whether a therapeutic should move to the next stage of development.

At the proposal stage, applicants will also have the option to consult, at the Institute’s expense, with clinical trial design experts as they write their proposals.

Request for Applications (RFA)

Program Details

Letter of Intent

A sample of the Proposal template is available here. Please note that the format and questions in the Proposal template are subject to change before the Proposal invitations so the template should be used only as an indicator of the expectations at the Proposal stage.

Program Information Session

To join the interactive information session conference call (Tuesday, August 4, 2015, 1:00 p.m. EDT) please register here.

The Institute welcomes inquiries about this request for applications or any of our other funding opportunities. We would be pleased to hear from you at either neuro@weston.ca or 416-935-4056.